Skip to main content
. 2015 Apr 23;10(41):4213–4223. doi: 10.18632/oncotarget.3925

Figure 1. Study rationale.

Figure 1

Current practice: Therapy switch at progress (PSA progress or progressive disease) occurs molecularly uninformed. Personalized approach: Evaluation of androgen receptor status in circulating tumor cells (CTC-AR-status) at time of progression enables matching of therapy to the individual resistance profile.